CorFlow
Diagnoses coronary microvascular dysfunction during standard interventional cardiology procedures.
What they do
Develops a proprietary medical system that measures coronary microvascular status in the catheterization lab. The device allows interventional cardiologists to diagnose and assess microvascular obstruction immediately following a heart attack, guiding post procedure treatment.
The record
- Vertical
- Cardiovascular
- Sub-segment
- Microvascular diagnostics
- Product type
- Diagnostics
- Stage
- Series B
- Headquarters
- Baar, Switzerland
- Region
- Europe
- Founded
- 2016
- Total funding
- $44M raised
Notable investors: Broadview Ventures, 415 Capital, Kromap, Sisu Medical Ventures.